Agenus 대차 대조표 상태

재무 상태 기준 확인 0/6

Agenus 의 총 주주 지분은 $-271.8M 이고 총 부채는 $13.4M, 이는 부채 대 자기자본 비율을 -4.9% 로 가져옵니다. 총자산과 총부채는 각각 $238.5M 및 $510.3M 입니다.

주요 정보

-4.9%

부채 비율

US$13.40m

부채

이자 보상 비율	n/a
현금	US$44.78m
주식	-US$271.80m
총 부채	US$510.29m
총 자산	US$238.48m

최근 재무 상태 업데이트

Auditors Have Doubts About Agenus (NASDAQ:AGEN)

Mar 06

Recent updates

Agenus: Novel Drugs That Just Are Not Novel

Jul 24

There's No Escaping Agenus Inc.'s (NASDAQ:AGEN) Muted Revenues Despite A 102% Share Price Rise

May 21

Analysts Have Lowered Expectations For Agenus Inc. (NASDAQ:AGEN) After Its Latest Results

May 09

Benign Growth For Agenus Inc. (NASDAQ:AGEN) Underpins Stock's 25% Plummet

Mar 29

Agenus: 2024 May Finally Be The Year For A Major Turnaround

Jan 18

Improved Revenues Required Before Agenus Inc. (NASDAQ:AGEN) Shares Find Their Feet

Dec 22

News Flash: Analysts Just Made A Huge Upgrade To Their Agenus Inc. (NASDAQ:AGEN) Forecasts

Nov 09

A Look At The Fair Value Of Agenus Inc. (NASDAQ:AGEN)

Oct 04

Industry Analysts Just Made A Notable Upgrade To Their Agenus Inc. (NASDAQ:AGEN) Revenue Forecasts

May 10

Agenus Inc.'s Imminent 1181/Bal Data Release And MiNK IPO Should Lead To Enormous Valuation Gains

Aug 25

Agenus Multiple Value-Adding Events Ahead

Aug 18

Party Time: Brokers Just Made Major Increases To Their Agenus Inc. (NASDAQ:AGEN) Earnings Forecasts

Aug 11

재무 상태 분석

단기부채: AGEN 에는 음의 주주 지분이 있는데, 이는 단기 부채를 감당하지 못하는 단기 자산보다 더 심각한 상황입니다.

장기 부채: AGEN 의 주주 지분은 음수입니다. 이는 장기 부채를 감당하지 못하는 단기 자산보다 더 심각한 상황입니다.

부채 대 자본 내역 및 분석

부채 수준: AGEN 은 부정주주자본을 갖고 있는데, 이는 높은 부채 수준보다 더 심각한 상황입니다.

부채 감소: AGEN 의 주주 지분은 음수이므로 시간이 지남에 따라 부채가 감소했는지 확인할 필요가 없습니다.

대차 대조표

현금 런웨이 분석

과거에 평균적으로 적자를 기록했던 기업의 경우, 최소 1년 이상의 현금 유동성을 보유하고 있는지 평가합니다.

안정적인 현금 활주로: AGEN 현재 무료 현금 흐름을 기준으로 1년 미만의 cash runway를 보유하고 있습니다.

예측 현금 활주로: 무료 현금 흐름이 매년 20.7 %의 역사적 비율로 계속 감소할 경우 AGEN 의 현금 활주로는 1년 미만입니다.

Agenus 대차 대조표 상태

재무 상태 기준 확인 0/6

주요 정보

최근 재무 상태 업데이트

Agenus Regains Compliance with Nasdaq Minimum Bid Price Requirement

Agenus Receives Notice from Nasdaq Stock Market's Listing Qualifications Department

Agenus Receives Notice from Nasdaq Stock Market's Listing Qualifications Department

Auditors Have Doubts About Agenus (NASDAQ:AGEN)

Recent updates

Agenus Inc. to Report Q3, 2024 Results on Nov 12, 2024

Rosen Law Firm Announces the Filing of a Class Action Lawsuit Against Agenus Inc

Agenus Inc. Appoints Tom Harrison to Its Board of Directors

Agenus Inc. to Report Q2, 2024 Results on Aug 08, 2024

Agenus: Novel Drugs That Just Are Not Novel

Agenus Inc. Announces End-Of-Phase-2 Meeting Outcomes and Topline Interim Phase 2 Data for Bot/Bal in MSS Colorectal Cancer

Agenus Inc Announces Results from an Investigator-Sponsored Trial (IST) of Botensilimab and Balstilimab (BOT/BALl) in the Neoadjuvant Setting for Colon Cancer

Agenus Inc. Announces Availability of Botensilimab for Clinical Studies

Agenus Appoints Jennifer Buell to Its Board of Directors

There's No Escaping Agenus Inc.'s (NASDAQ:AGEN) Muted Revenues Despite A 102% Share Price Rise

Agenus Inc. announces FDA Grants Agenus Type B End-Of-Phase 2 Meeting to Discuss Bot/Bal Therapy for Relapsed or Refractory Metastatic Colorectal Cancer

Consensus revenue estimates fall by 27%

New major risk - Financial position

Analysts Have Lowered Expectations For Agenus Inc. (NASDAQ:AGEN) After Its Latest Results

Ligand and Agenus Enter into $100 Million Royalty Financing Agreement to Support Agenus’ Key Development Initiatives in the Ongoing Bot/Bal Clinical Development Program

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Agenus Regains Compliance with Nasdaq Minimum Bid Price Requirement

Agenus Inc., Annual General Meeting, Jun 11, 2024

Agenus Inc. to Report Q1, 2024 Results on May 07, 2024

New major risk - Share price stability

Agenus Announces Updated Phase 1 Data and Progress on BOT/BAL Development in Metastatic MSS Colorectal Cancer

Benign Growth For Agenus Inc. (NASDAQ:AGEN) Underpins Stock's 25% Plummet

Consensus revenue estimates increase by 30%, EPS downgraded

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Agenus Inc. Announces Preclinical Data on BMS-986442 (AGEN1777) at AACR 2024

Agenus Inc. to Report Q4, 2023 Results on Mar 14, 2024

Founder recently bought US$324k worth of stock

Agenus: 2024 May Finally Be The Year For A Major Turnaround

Improved Revenues Required Before Agenus Inc. (NASDAQ:AGEN) Shares Find Their Feet

Agenus Inc. Announces Data from an Investigator Sponsored Trial Evaluating Botensilimab in Combination with Balstilimab in Neoadjuvant Colorectal Cancer

Agenus Receives Notice from Nasdaq Stock Market's Listing Qualifications Department

Agenus Receives Notice from Nasdaq Stock Market's Listing Qualifications Department

News Flash: Analysts Just Made A Huge Upgrade To Their Agenus Inc. (NASDAQ:AGEN) Forecasts

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased by 17% to US$6.67

Agenus Inc. to Report Q3, 2023 Results on Nov 07, 2023

Agenus Inc. Unveils New and Updated Botensilimab Data in Colorectal, Pancreatic, Lung, Melanoma, and Sarcoma

Agenus Inc. Announces Expanded Data from the Company's Phase 1B Study of Botensilimab in Combination with Balstilimab (Bal, Anti-Pd-1) in Patients with Advanced Sarcomas

Now 22% undervalued after recent price drop

Agenus Inc. Completes Enrollment in Randomized Phase 2 Clinical Trial of Botensilimab/Balstilimab in Advanced Colorectal Cancer

A Look At The Fair Value Of Agenus Inc. (NASDAQ:AGEN)

Agenus Inc. Prioritizes Resources to Accelerate Registration and Commercialization of BOT/BAL Program in Multiple Cancers

Second quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

Agenus Inc. to Report Q2, 2023 Results on Aug 08, 2023

Agenus' Botensilimab/Balstilimab Combination Achieves Unprecedented Survival in Advanced Colorectal Cancer

Industry Analysts Just Made A Notable Upgrade To Their Agenus Inc. (NASDAQ:AGEN) Revenue Forecasts

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Full year 2022 earnings: EPS in line with analyst expectations despite revenue beat

Agenus Presents Clinical Data Demonstrating Durable Responses of Botensilimab/Balstilimab Combination in Metastatic Microsatellite Stable Colorectal Cancer at ASCO GI

Agenus Inc. Announces the Resignation of Wadih Jordan as Director, Effective December 31, 2022

Price target decreased to US$6.33

Insufficient new directors

Agenus Inc. Data At SITC 2022 Highlight Durable Responses of Botensilimab / Balstilimab Combination in Nine Different Treatment-Resistant Cancers

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Agenus Inc. to Report Q3, 2022 Results on Nov 08, 2022

Agenus Inc. Announces GSK Disclose Positive Pivotal Phase III Trial Results for Its Respiratory Syncytial Virus Vaccine Candidate

VBI Vaccines, Agenus to examine VBI-1901 + balstilimab combo for glioblastoma

Investor sentiment improved over the past week

Price target decreased to US$6.33

Agenus New Trials Set It Up For The Long Haul

Investor sentiment deteriorated over the past week

Agenus: It's Always Tomorrow

Agenus Initiates Botensilimab Phase 2 Activate Trials in Advanced MSS Colorectal Cancer and Advanced Melanoma

Investor sentiment improved over the past week

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Agenus GAAP EPS of -$0.17, revenue of $20.93M

Agenus Inc. Announces First Patient Dosed in Phase 1 Study of AGEN1571 (Anti-ILT2) in Advanced Solid Tumors

Agenus Inc. to Report Q2, 2022 Results on Aug 09, 2022

Agenus: Successfully Pulled Itself Away From Disaster

Agenus Shows Unprecedented Activity for Botensilimab/Balstilimab Combination in Microsatellite Stable Colorectal Cancer at ESMO World GI Congress

Agenus Inc. Announces Positive Headline Results from A Pre-Specified Efficacy Interim Analysis of the Aresvi 006 Phase III Trial Evaluating Their Investigational RSV Vaccine in Adults Aged 60 Years and Above